LZLei Zhang

Lei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Zhang has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng Huang

    School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China

    7 shared publications
  • Lei Xu

    School of Pharmacy, Anhui Medical University, Hefei, People’s Republic of China

    7 shared publications
  • Jie Shen

    School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province Anhui Medical University Hefei China

    6 shared publications
  • Tao Xu

    School of Pharmacy, Anhui Medical University, Hefei, People’s Republic of China

    6 shared publications
  • Tian-Yu Yang

    School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-inflammatory of Immune Medicines of Ministry of Education, Anhui Medical University, Hefei 230032, China

    6 shared publications
  • Junfa Yang

    School of Pharmacy, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei, China

    5 shared publications

Latest Publications

  • Open Access

    Polydatin Alleviates APAP‐Induced Hepatotoxicity by Targeting C/EBPβ to Suppress the NLRP3 Inflammasome Signaling Pathway

    by Tian‐Yu Yang, Chen Wang, Yi Ding, Wei‐Kang Zhang, Ling Zheng, Li Yue, Lei Zhang

    Objective: To investigate the protective effects and underlying mechanisms of polydatin (PD), a natural Sirt1 agonist derived from Polygonum cuspidatum, against acetaminophen (APAP)‐induced acute liver injury (ALI), with a focus on the regulation of the NLRP3 inflammasome signaling pathway and associated inflammatory pathways. Methods: Polydatin's hepatoprotective effects against APAP‐induced ALI were evaluated using a murine model and the AML12 cell line. Liver damage was assessed through histopathological staining and biochemical assays. The protective mechanisms of polydatin were investigated through network pharmacology and RNA sequencing. Protein levels related to inflammation are measured via Western blotting. The effect of polydatin on reactive oxygen species (ROS) was analyzed using immunofluorescence and flow cytometry. The interaction of polydatin with target proteins was analyzed through molecular docking, molecular dynamics simulations, surface plasmon resonance (SPR), and cellular thermal shift assay (CETSA). Results: PD significantly ameliorated APAP‐induced liver injury by restoring redox homeostasis and suppressing the release of inflammatory factors. Transcriptome sequencing revealed a time‐dependent upregulation of NLRP3, a core component of the NOD‐like receptor signaling pathway, during APAP challenge. PD inhibited the NLRP3 inflammasome signaling cascade and reduced downstream inflammatory mediators. Mechanistically, PD decreased both the expression and acetylation of C/EBPβ, thereby blocking C/EBPβ‐mediated activation of NLRP3 inflammasome signaling pathway and attenuating hepatocyte inflammation and liver damage. Conclusion: This study identifies a Sirt1/C/EBPβ/NLRP3 signaling axis through which polydatin exerts its hepatoprotective effects. These findings provide a mechanistic rationale for developing PD as a preventive or therapeutic agent for APAP‐induced ALI.


  • Kv1.3 regulates macrophage immune function through PI3K/AKT signaling pathway to alleviate metabolic dysfunction-associated steatohepatitis

    by Ting Ke, Wen-Jun Zhen, Xi-Xi Chen, Hao Wang, Shi Chen, Yuan-Yuan Tian, Ye-Tao Wang, Lei Zhang, Bao-Ming Wu

    The progression of metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to macrophage-mediated inflammatory responses. The role of Kv1.3, a key voltage-gated potassium channel regulating macrophage function, in MASH remains unclear. This study investigated Kv1.3 blockade's therapeutic potential in MASH and its mechanism, focusing on the PI3K/AKT signaling pathway. A Western diet (WD)-induced mouse model of MASH was established, and hepatic Kv1.3 was knocked down via AAV8-Kv1.3-shRNA. Hepatic steatosis, inflammation, and macrophage infiltration were evaluated. In vitro, LPS-stimulated RAW264.7 macrophages were treated with the Kv1.3 inhibitor ShK-186 to assess inflammatory cytokine (IL-6, TNF-α) production and migration. The GEO dataset (GSE222922) validated the PI3K/AKT signaling pathway involvement. Kv1.3 expression was significantly increased in WD-induced MASH mouse livers. Hepatic Kv1.3 knockdown alleviated liver injury, steatosis, and inflammation. In vitro, ShK-186 inhibited LPS-induced macrophage migration and cytokine production, and significantly reduced the PI3K/AKT phosphorylation. These effects were reversed by the PI3K agonist 740Y-P, confirming that Kv1.3 regulates macrophage function via the PI3K/AKT signaling. Kv1.3 modulates macrophage inflammation and migration through the PI3K/AKT signaling pathway, promoting MASH progression. Kv1.3 knockdown ameliorates MASH pathology, highlighting it as a promising therapeutic target. Kv1.3 drives MASH via macrophage PI3K/AKT signaling, worsening liver inflammation Macrophage Kv1.3 knockdown alleviates MASH pathology in WD-fed mice Kv1.3 is a potential therapeutic target for MASH, modulating liver inflammation.

  • Open Access

    Engineered mesenchymal stem cells-laden chondroitin sulfate hydrogel promotes diabetic wound healing through ROS scavenging and macrophage polarization

    by Xi Cao, Ziqi Shen, Xiaohua Wang, Yuanyuan Chu, Runkong Wang, Liyang Zhu, Ruixue Zhong, Zhong Zhang, Mingquan Wu, Xu Zhou, et al.


  • Open Access

    Ultrasound-activated dual-nanozyme platform for targeted ROS scavenging and NO delivery in liver fibrosis therapy

    by Xiujuan Yin, Shuqin Xue, Jiaqi Ji, Mingyu Zhao, Min Shao, Likang Yin, Saisai Zhang, Lei Liu, Bin Li, Lei Zhang, et al.


  • A dual-targeted nano-system co-regulating macrophage ROS and fibroblast ferroptosis for rheumatoid arthritis treatment

    by Xiaohua Wang, Tingting Gao, Jingjing Wu, Xu Zhou, Yuanyuan Chu, Lei Zhang, Xi Cao

    Schematic illustration of the preparation process and therapeutic mechanism of Hep-Lips/CLT.


  • The GSK3β inhibitor attenuate APAP-induced liver injury by regulating PGC1α-mediated oxidative stress

    by Zhu Wang, Ming-Yu Zhao, Jun-Wei Wang, Yu-Ting He, Rong-Quan Yang, Jia-Qi Ji, Yi Ding, Chen Wang, Yu-Hong Zhao, Wei-Kang Zhang, et al.


  • Open Access

    Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma

    by Jing Rong, Tongtong Liu, Xiujuan Yin, Min Shao, Kun Zhu, Bin Li, Shiqi Wang, Yujie Zhu, Saisai Zhang, Likang Yin, et al.

    Background: Camptothecin (CPT) is one of the frequently used small chemotherapy drugs for treating hepatocellular carcinoma (HCC), but its clinical application is limited due to severe toxicities and acquired resistance. Combined chemo-gene therapy has been reported to be an effective strategy for counteracting drug resistance while sensitizing cancer cells to cytotoxic agents. Thus, we hypothesized that combining CPT with miR-145 could synergistically suppress tumor proliferation and enhance anti-tumor activity. Methods: Lactobionic acid (LA) modified lipid nanoparticles (LNPs) were developed to co-deliver CPT and miR-145 into asialoglycoprotein receptors-expressing HCC in vitro and in vivo. We evaluated the synergetic antitumor effect of miR-145 and CPT using CCK8, Western blotting, apoptosis and wound scratch assay in vitro, and the mechanisms underlying the synergetic antitumor effects were further investigated. Tumor inhibitory efficacy, safety evaluation and MRI-visible ability were assessed using diethylnitrosamine (DEN) + CCl4-induced HCC mouse model. Results: The LA modification improved the targeting delivery of cargos to HCC cells and tissues. The LA-CMGL-mediated co-delivery of miR-145 and CPT is more effective on tumor inhibitory than LA-CPT-L or LA-miR-145-L treatment alone, both in vitro and in vivo, with almost no side effects during the treatment period. Mechanistically, miR-145 likely induces apoptosis by targeting SUMO-specific peptidase 1 (SENP1)-mediated hexokinase (HK2) SUMOylation and glycolysis pathways and, in turn, sensitizing the cancer cells to CPT. In vitro and in vivo tests confirmed that the loaded Gd-DOTA served as an effective T1-weighted contrast agent for noninvasive tumor detection as well as real-time monitoring of drug delivery and biodistribution. Conclusions: The LA-CMGL-mediated co-delivery of miR-145 and CPT displays a synergistic therapy against HCC. The novel MRI-visible, actively targeted chemo-gene co-delivery system for HCC therapy provides a scientific basis and a useful idea for the development of HCC treatment strategies in the future.


  • A novel HDAC6 inhibitor attenuate APAP-induced liver injury by regulating MDH1-mediated oxidative stress

    by Guo-Dong Zhang, Li-Li Wang, Ling Zheng, Shi-Qi Wang, Rong-Quan Yang, Yu-Ting He, Jun-Wei Wang, Ming-Yu Zhao, Yi Ding, Mei Liu, et al.


  • LincRNA‐ROR / miR ‐145/ ZEB2 regulates liver fibrosis by modulating HERC5 ‐mediated p53 ISGylation

    by Jie Shen, Zhu Wang, Mei Liu, Yu‐Jie Zhu, Ling Zheng, Li‐Li Wang, Jie‐Ling Cheng, Tong‐Tong Liu, Guo‐Dong Zhang, Tian‐Yu Yang, et al.

    The tumor suppressor p53 has been implicated in the pathogenesis of liver fibrosis. HERC5‐mediated posttranslational ISG modification of the p53 protein is critical for controlling its activity. Here, we demonstrated that the expression of HERC5 and ISG15 is highly elevated, whereas p53 is downregulated, in fibrotic liver tissues of mice and transforming growth factor‐β1 (TGF‐β1)‐induced LX2 cells. HERC5 siRNA clearly increased the protein expression of p53, but the mRNA expression of p53 was not obviously changed. The inhibition of lincRNA‐ROR (ROR) downregulated HERC5 expression and elevated p53 expression in TGF‐β1‐stimulated LX‐2 cells. Furthermore, the expression of p53 was almost unchanged after TGF‐β1‐stimulated LX‐2 cells were co‐transfected with a ROR‐expressing plasmid and HERC5 siRNA. We further confirmed that miR‐145 is a target gene of ROR. In addition, we also showed that ROR regulates the HERC5‐mediated ISGylation of p53 through mir‐145/ZEB2. Together, we propose that ROR/miR‐145/ZEB2 might be involved in the course of liver fibrosis by regulating ISGylation of the p53 protein.


  • Open Access

    Hif-2α regulates lipid metabolism in alcoholic fatty liver disease through mitophagy

    by Mei-Fei Wu, Guo-Dong Zhang, Tong-Tong Liu, Jun-Hao Shen, Jie-Ling Cheng, Jie Shen, Tian-Yu Yang, Cheng Huang, Lei Zhang

    Background: Disordered lipid metabolism plays an essential role in both the initiation and progression of alcoholic fatty liver disease (AFLD), and fatty acid β-oxidation is increasingly considered as a crucial factor for controlling lipid metabolism. Hif-2α is a member of the Hif family of nuclear receptors, which take part in regulating hepatic fatty acid β-oxidation. However, its functional role in AFLD and the underlying mechanisms remain unclear. Results: Hif-2α was upregulated in EtOH-fed mice and EtOH-treated AML-12 cells. Inhibition or silencing of Hif-2α led to increased fatty acid β-oxidation and BNIP3-dependent mitophagy. Downregulation of Hif-2α activates the PPAR-α/PGC-1α signaling pathway, which is involved in hepatic fatty acid β-oxidation, by mediating BNIP3-dependent mitophagy, ultimately delaying the progression of AFLD. Conclusions: Hif-2α induces liver steatosis, which promotes the progression of AFLD. Here, we have described a novel Hif-2α-BNIP3-dependent mitophagy regulatory pathway interconnected with EtOH-induced lipid accumulation, which could be a potential therapeutic target for the prevention and treatment of AFLD.